Kristina Gabbard
Family · Chrisman, ILNPI 1154806958
Payments from drug & device makers
Across 54 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$209
- AstraZeneca$95
- Neurocrine Biosciences, Inc.$86
- Takeda Pharmaceuticals U.S.A., Inc.$85
- Otsuka America Pharmaceutical, Inc.$65
- Lilly USA, LLC$59
- plus $428 from 15 others
What the payments were for
- Food & beverage$1,027100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$125
How this compares
$1,027 in reported general payments places this provider in the 70th percentile of 4,941 family providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 119 | $97,324 |
| OzempicSemaglutide | 53 | $51,227 |
| MounjaroTirzepatide | 40 | $42,447 |
| TrulicityDulaglutide | 31 | $32,213 |
| FarxigaDapagliflozin Propanediol | 35 | $25,577 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 52 | $24,825 |
| EliquisApixaban | 29 | $22,845 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $15,315 |
| Repatha SureclickEvolocumab | 13 | $8,795 |
| Varenicline Tartrate | 12 | $2,980 |
| PremarinEstrogens, Conjugated | 12 | $2,467 |
| Atorvastatin Calcium | 163 | $1,846 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $1,040 |
| Gabapentin | 52 | $930 |
| Metformin Hcl ErMetformin Hcl | 53 | $720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $59 | $74,66071 claims |
| Novo NordiskOzempic | $209 | $51,22753 claims |
| GSKAnoro Ellipta, Trelegy Ellipta | $54 | $40,14077 claims |
| AstraZenecaFarxiga | $95 | $25,57735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,941 family providers in Illinois.
Other family in Chrisman
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.